

E-References

- e1. Vernengo L, Chourbagi O, Panuncio A, et al. Desmin myopathy with severe cardiomyopathy in a Uruguayan family due to a codon deletion in a new location within the desmin 1A rod domain. *Neuromuscul Disord* 2010;20:178–187.
- e2. Melberg A, Oldfors A, Blomström-Lundqvist C, et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. *Ann Neurol* 1999;46:684–692.
- e3. Mahjneh I, Lamminen AE, Udd B, et al. Muscle magnetic resonance imaging shows distinct diagnostic patterns in Welander and tibial muscular dystrophy. *Acta Neurol Scand* 2004;110:87–93.
- e4. Borg K, Ahlberg G, Borg J, Edström L. Welander's distal myopathy: clinical, neurophysiological and muscle biopsy observations in young and middle aged adults with early symptoms. *J Neurol Neurosurg Psychiatry* 1991;54:494–498.
- e5. Borg K, Solders G, Borg J, Edström L, Kristensson K. Neurogenic involvement in distal myopathy (Welander). Histochemical and morphological observations on muscle and nerve biopsies. *J Neurol Sci* 1989;91:53–70.
- e6. Borg K, Tomé FM, Edström L. Intranuclear and cytoplasmic filamentous inclusions in distal myopathy (Welander). *Acta Neuropathol* 1991;82:102–106.
- e7. von Tell D, Somer H, Udd B, Edström L, Borg K, Ahlberg G. Welander distal myopathy outside the Swedish population: phenotype and genotype. *Neuromuscul Disord* 2002;12:544–547.
- e8. Udd B, Haravuori H, Kalimo H, et al. Tibial muscular dystrophy--from clinical description to linkage on chromosome 2q31. *Neuromuscul Disord* 1998;8:327–332.
- e9. Van den Bergh PY, Bouquiaux O, Verellen C, et al. Tibial muscular dystrophy in a Belgian family. *Ann Neurol* 2003;54:248–251.
- e10. Pénişon-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: limb-girdle muscular dystrophy 2J and variations of phenotype. *J Neurol Neurosurg Psychiatry* 2010;811:1200–1202.
- e11. Pfeffer G, Elliott HR, Griffin H, et al. Titin mutation segregates with hereditary myopathy with early respiratory failure. *Brain* 2012;135(Pt 6):1695–1713.
- e12. Udd B. Limb-girdle type muscular dystrophy in a large family with distal myopathy: homozygous manifestation of a dominant gene? *J Med Genet* 1992;29:383–389.
- e13. Udd B, Rapola J, Nokelainen P, Arikawa E, Somer H. Nonvacuolar myopathy in a large family with both late adult onset distal myopathy and severe proximal muscular dystrophy. *J Neurol Sci* 1992;113:214–221.
- e14. Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy. Late adult-onset distal myopathy in 66 Finnish patients. *Arch Neurol* 1993;50:604–608.
- e15. Ohlsson M, Hedberg C, Brådvik B, et al. Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. *Brain* 2012;135(Pt 6):1682–1694.
- e16. Carmignac V, Salih MA, Quijano-Roy S, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. *Ann Neurol* 2007;61:340–351.
- e17. Udd B, Kääriäinen H, Somer H. Muscular dystrophy with separate clinical phenotypes in a large family. *Muscle Nerve* 1991;14:1050–1058.

- e18. Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. *Ann Neurol* 2000;48:170–180.
- e19. Hausmanowa-Petrusewicz I, Madej-Pilarczyk A, Marchel M, Opolski G. Emery-Dreifuss dystrophy: a 4-year follow-up on a laminopathy of special interest. *Neurol Neurochir Pol* 2009;43:415–420.
- e20. Rudenskaya GE, Polyakov AV, Tverskaya SM, et al. Laminopathies in Russian families. *Clin Genet* 2008;74:127–133.
- e21. Komaki H, Hayashi YK, Tsuburaya R, et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. *Neuromuscul Disord* 2011;21:563–568.
- e22. van der Kooi AJ, van Meegen M, Ledderhof TM, McNally EM, de Visser M, Bolhuis PA. Genetic localization of a newly recognized autosomal dominant limb-girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. *Am J Hum Genet* 1997;60:891–895.
- e23. Yuan WL, Huang CY, Wang JF, et al. R25G mutation in exon 1 of LMNA gene is associated with dilated cardiomyopathy and limb-girdle muscular dystrophy 1B. *Chin Med J (Engl)* 2009;122:2840–2845.
- e24. Fanin M, Pegoraro E, Matsuda-Asada C, Brown RH Jr, Angelini C. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. *Neurology* 2001;56:660–665.
- e25. Aoki M, Liu J, Richard I, et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. *Neurology* 2001;57:271–278.
- e26. Argov Z, Sadeh M, Mazor K, et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. *Brain* 2000;123:1229–1237.
- e27. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. *Neuropathol Appl Neurobiol* 2002;28:461–470.
- e28. Khadilkar S, Singh RK, Kulkarni KS, Chitale AR. A study of clinical and laboratory features of 14 Indian patients with dysferlinopathy. *J Clin Neuromuscul Dis* 2004;6:1–8.
- e29. Klinge L, Aboumoussa A, Eagle M, et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. *J Neurol Neurosurg Psychiatry* 2010;81:946–953.
- e30. Vilchez JJ, Gallano P, Gallardo E, et al. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. *Arch Neurol* 2005;62:1256–1259.
- e31. Weiler T, Greenberg CR, Nysten E, et al. Limb-girdle muscular dystrophy and Miyoshi myopathy in an aboriginal Canadian kindred map to LGMD2B and segregate with the same haplotype. *Am J Hum Genet* 1996;59:872–878.
- e32. Gayathri N, Alefia R, Nalini A, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. *Indian J Pathol Microbiol* 2011;54:350–354.
- e33. Cupler EJ, Bohlega S, Hessler R, McLean D, Stigsby B, Ahmad J. Miyoshi myopathy in Saudi Arabia: clinical, electrophysiological, histopathological and radiological features. *Neuromuscul Disord* 1998;8:321–326.
- e34. Pradhan S. Clinical and magnetic resonance imaging features of ‘diamond on quadriceps’ sign in dysferlinopathy. *Neurol India* 2009;57:172–175.
- e35. Ro LS, Lee-Chen GJ, Lin TC, et al. Phenotypic features and genetic findings in 2 chinese families with Miyoshi distal myopathy. *Arch Neurol* 2004;61:1594–1599.

- e36. Takahashi T, Aoki M, Tateyama M, et al. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. *Neurology* 2003;60:1799–1804.
- e37. Ueyama H, Kumamoto T, Nagao S, et al. A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy. *Neuromuscul Disord* 2001;11:139–145.
- e38. Vainzof M, Anderson LV, McNally EM, et al. Dysferlin protein analysis in limb-girdle muscular dystrophies. *J Mol Neurosci* 2001;17:71–80.
- e39. Penttilä S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. *Neurology* 2012;78:897–903.
- e40. Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. *Am J Hum Genet* 2010;86:213–221.
- e41. Mahjneh I, Jaiswal J, Lamminen A, et al. A new distal myopathy with mutation in anoctamin 5. *Neuromuscul Disord* 2010;20:791–795.
- e42. Schessl J, Kress W, Schoser B. Novel ANO5 mutations causing hyper-CK-emia, limb girdle muscular weakness and Miyoshi type of muscular dystrophy. *Muscle Nerve* 2012;45:740–742.
- e43. Canki-Klain N, Récan D, Milicić D, et al. Clinical variability and molecular diagnosis in a four-generation family with X-linked Emery-Dreifuss muscular dystrophy. *Croat Med J* 2000;41:389–395.
- e44. Draminska A, Kuch-Wocial A, Szulc M, et al. Echocardiographic assessment of left ventricular morphology and function in patients with Emery-Dreifuss muscular dystrophy. *Int J Cardiol* 2005;102:207–210.
- e45. Quinzii CM, Vu TH, Min KC, et al. X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. *Am J Hum Genet* 2008;82:208–213.
- e46. Liang WC, Mitsuhashi H, Keduka E, et al. TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy. *Ann Neurol* 2011;69:1005–1013.
- e47. Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. *Neurology* 2004;62:1363–1371.
- e48. Berciano J, Gallardo E, Domínguez-Perles R, et al. Autosomal-dominant distal myopathy with a myotilin S55F mutation: sorting out the phenotype. *J Neurol Neurosurg Psychiatry* 2008;79:205–208.
- e49. Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. *Neurology* 2008;71:758–765.
- e50. Foroud T, Pankratz N, Batchman AP, et al. A mutation in myotilin causes spheroid body myopathy. *Neurology* 2005;65:1936–1940.
- e51. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. *Hum Mol Genet* 2000;9:2141–2147.
- e52. Olivé M, Goldfarb LG, Shatunov A, Fischer D, Ferrer I. Myotilinopathy: refining the clinical and myopathological phenotype. *Brain* 2005;128:2315–2326.
- e53. Pénişon-Besnier I, Talvinen K, Dumez C, et al. Myotilinopathy in a family with late onset myopathy. *Neuromuscul Disord* 2006;16:427–431.
- e54. Schramm N, Born C, Weckbach S, Reilich P, Walter MC, Reiser MF. Involvement patterns in myotilinopathy and desminopathy detected by a novel neuromuscular whole-body MRI protocol. *Eur Radiol* 2008;18:2922–2936.

- e55. Reilich P, Schoser B, Schramm N, et al. The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. *Neuromuscul Disord* 2010;20:255–259.
- e56. Selcen D, Engel AG. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. *Ann Neurol* 2003;54:804–810.
- e57. Sacconi S, Féasson L, Antoine JC, et al. A novel CRYAB mutation resulting in multisystemic disease. *Neuromuscul Disord* 2012;22:66–72.
- e58. Selcen D, Engel AG. Mutations in ZASP define a novel form of muscular dystrophy in humans. *Ann Neurol* 2005;57:269–276.
- e59. Odgerel Z, Sarkozy A, Lee HS, et al. Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. *Neuromuscul Disord* 2010;20:438–442.
- e60. Vorgerd M, van der Ven PF, Bruchertseifer V, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. *Am J Hum Genet* 2005;77:297–304.
- e61. Kley RA, Hellenbroich Y, van der Ven PF, et al. Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients. *Brain* 2007;130:3250–3264.
- e62. Williams DR, Reardon K, Roberts L, et al. A new dominant distal myopathy affecting posterior leg and anterior upper limb muscles. *Neurology* 2005;64:1245–1254.
- e63. Duff RM, Tay V, Hackman P, et al. Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy. *Am J Hum Genet* 2011;88:729–740.
- e64. Guergueltcheva V, Peeters K, Baets J, et al. Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. *Neurology* 2011;77:2105–2114.
- e65. Luan X, Hong D, Zhang W, Wang Z, Yuan Y. A novel heterozygous deletion-insertion mutation (2695-2712 del/GTTTGT ins) in exon 18 of the filamin C gene causes filaminopathy in a large Chinese family. *Neuromuscul Disord* 2010;20:390–396.
- e66. Jaiswal JK, Marlow G, Summerill G, et al. Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. *Traffic* 2007;8:77–88.
- e67. Jarry J, Rioux MF, Bolduc V, et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. *Brain* 2007;130(Pt 2):368–380.
- e68. Carboni N, Mura M, Mercuri E, et al. Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy. *Neuromuscul Disord* 2012;22:152–158.
- e69. Menache CC, Brown CA, Donnelly JH, Shapiro F, Darras BT. Identification of a novel truncating mutation (S171X) in the Emerin gene in five members of a Caucasian American family with Emery-Dreifuss muscular dystrophy. *Hum Mutat* 2000;16:94.
- e70. Sakata K, Shimizu M, Ino H, et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. *Circulation* 2005;111:3352–3358.
- e71. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. *Nat Genet* 1998;18:365–368.
- e72. Aboumoussa A, Hoogendijk J, Charlton R, et al. Caveolinopathy--new mutations and additional symptoms. *Neuromuscul Disord* 2008;18:572–578.
- e73. González-Pérez P, Gallano P, González-Quereda L, et al. Phenotypic variability in a Spanish family with a Caveolin-3 mutation. *J Neurol Sci* 2009;276:95–98.
- e74. Farpour F, Tehranzadeh J, Donkervoort S, et al. Radiological features of Paget disease of bone associated with VCP myopathy. *Skeletal Radiol* 2012;41:329–337.

- e75. Kimonis VE, Kovach MJ, Waggoner B, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. *Genet Med* 2000;2:232–241.
- e76. Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. *Am J Med Genet A* 2008;146A:745–757.
- e77. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. *Alzheimer Dis Assoc Disord* 2005;19 Suppl 1:S44–S47.
- e78. Guyant-Maréchal L, Laquierrière A, Duyckaerts C, et al. Valosin-containing protein gene mutations: clinical and neuropathologic features. *Neurology* 2006;67:644–651.
- e79. Haubenberger D, Bittner RE, Rauch-Shorny S, et al. Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. *Neurology* 2005;65:1304–1305.
- e80. Miller TD, Jackson AP, Barresi R, et al. Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree. *J Neurol Neurosurg Psychiatry* 2009;80:583–584.
- e81. Kim EJ, Park YE, Kim DS, et al. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. *Arch Neurol* 2011;68:787–796.
- e82. Kumar KR, Needham M, Mina K, et al. Two Australian families with inclusion-body myopathy, Paget's disease of bone and frontotemporal dementia: novel clinical and genetic findings. *Neuromuscul Disord* 2010;20:330–334.
- e83. Stojkovic T, Hammouda el H, Richard P, et al. Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementia. *Neuromuscul Disord* 2009;19:316–323.
- e84. Viassolo V, Previtali SC, Schiatti E, et al. Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. *Clin Genet* 2008;74:54–60.
- e85. Waggoner B, Kovach MJ, Winkelman M, et al. Heterogeneity in familial dominant Paget disease of bone and muscular dystrophy. *Am J Med Genet* 2002;108:187–191.
- e86. Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. *Clin Genet* 2007;72:420–426.
- e87. Shi Z, Hayashi YK, Mitsushashi S, et al. Characterization of the Asian myopathy patients with VCP mutations. *Eur J Neurol* 2012;19:501–509.
- e88. van der Zee J, Pirici D, Van Langenhove T, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. *Neurology* 2009;73:626–632.
- e89. Watts GD. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet* 2004;36:377–381.
- e90. Palmio J, Sandell S, Suominen T, et al. Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family. *Neuromuscul Disord* 2011;21:551–555.
- e91. Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. *Ann Neurol* 2006;59:808–815.
- e92. Klinge L, Dekomien G, Aboumoussa A, et al. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype? *Neuromuscul Disord* 2008;18:934–941.

- e93. Eymard B, Romero NB, Leturcq F, et al. Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. *Neurology* 1997;48:1227–1234.
- e94. Hackman P, Juvonen V, Saraparanta J, et al. Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients. *Muscle Nerve* 2005;31:199–204.
- e95. Dinçer P, Akçören Z, Demir E, et al. A cross section of autosomal recessive limb-girdle muscular dystrophies in 38 families. *J Med Genet* 2000;37:361–367.
- e96. Todorova A, Georgieva B, Tournev I, et al. A large deletion and novel point mutations in the calpain 3 gene (CAPN3) in Bulgarian LGMD2A patients. *Neurogenetics* 2007;8:225–229.
- e97. van der Kooi AJ, Frankhuizen WS, Barth PG, et al. Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families. *Neurology* 2007;68:2125–2128.
- e98. Groen E, Charlton R, Barresi R, et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. *Brain* 2007;130:3237–3249.
- e99. Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. *Neuromuscul Disord* 2005;15:164–171.
- e100. Topaloğlu H, Dinçer P, Richard I, et al. Calpain-3 deficiency causes a mild muscular dystrophy in childhood. *Neuropediatrics* 1997;28:212–216.
- e101. Angelini C, Fanin M, Freda MP, et al. Prognostic factors in mild dystrophinopathies. *J Neurol Sci* 1996;142:70–78.
- e102. Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. *Neurology* 1989;39:1011–1017.
- e103. Sveen ML, Thune JJ, Køber L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. *Arch Neurol* 2008;65:1196–1201.
- e104. Agretto A, Politano L, Bossone E, et al. Pulsed Doppler tissue imaging in dystrophinopathic cardiomyopathy. *J Am Soc Echocardiogr* 2002;15:891–899.
- e105. Ammendola E, Russo V, Politano L, Santangelo L, Calabrò R. Is heart rate variability a valid parameter to predict sudden death in patients with Becker's muscular dystrophy? *Heart* 2006;92:1686–1687.
- e106. Anuar AA, Wong KT, Ching AS, et al. Exercise induced cramps and myoglobinuria in dystrophinopathy--a report of three Malaysian patients. *Neurol Asia* 2010;15:125–131.
- e107. Angelini C, Fanin M, Pegoraro E, Freda MP, Cadaldini M, Martinello F. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. *Neuromuscul Disord* 1994;4:349–358.
- e108. Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. *Brain* 2011;134:3547–3559.
- e109. Arahata K, Hoffman EP, Kunkel LM, et al. Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses. *Proc Natl Acad Sci U S A* 1989;86:7154–7158.
- e110. Bardoni A, Felisari G, Sironi M, et al. Loss of Dp140 regulatory sequences is associated with cognitive impairment in dystrophinopathies. *Neuromuscul Disord* 2000;10:194–199.
- e111. Berlit P, Stegaru-Hellring B. The heart in muscular dystrophy: an electrocardiographic and ultrasound study of 20 patients. *Eur Arch Psychiatry Clin Neurosci* 1991;241:177–180.

- e112. Carsana A, Frisso G, Tremolaterra MR, et al. Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. *Ann Hum Genet* 2005;69:253–259.
- e113. Comi GP, Prella A, Bresolin N, et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. *Brain* 1994;117:1–14.
- e114. Comi LI, Nigro G, Politano L, Petretta VR. The cardiomyopathy of Duchenne/Becker consultands. *Int J Cardiol* 1992;34:297–305.
- e115. Connuck DM, Sleeper LA, Colan SD, et al; Pediatric Cardiomyopathy Registry Study Group. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. *Am Heart J* 2008;155:998–1005.
- e116. de Visser M, de Voogt WG, la Rivière GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. *Muscle Nerve* 1992;15:591–596.
- e117. Finsterer J, Stöllberger C, Keller H, Slany J, Mamoli B. Cardiac involvement in patients with myotonic dystrophy, Becker's muscular dystrophy and mitochondrial myopathy. *Herz* 1997;22:96–103.
- e118. Gold R, Kress W, Meurers B, Meng G, Reichmann H, Müller CR. Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. *Muscle Nerve* 1992;15:214–218.
- e119. de Visser M, Bakker E, Defesche JC, Bolhuis PA, van Ommen GJ. An unusual variant of Becker muscular dystrophy. *Ann Neurol* 1990;27:578–581.
- e120. Hoogerwaard EM, de Voogt WG, Wilde AA, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. *J Neurol* 1997;244:657–653.
- e121. Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. *Circulation* 2005;112:2799–2804.
- e122. Ginjaar IB, Kneppers AL, v d Meulen JD, et al. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family. *Eur J Hum Genet* 2000;8:793–796.
- e123. Gospe SM Jr, Lazaro RP, Lava NS, Grootsholten PM, Scott MO, Fischbeck KH. Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene. *Neurology* 1989;39:1277–1280.
- e124. Mavrogeni S, Papavasiliou A, Skouteli E, Magoutas A, Dangas G. Cardiovascular magnetic resonance imaging evaluation of two families with Becker muscular dystrophy. *Neuromuscul Disord* 2010;20:717–719.
- e125. Melacini P, Fanin M, Danieli GA, et al. Cardiac involvement in Becker muscular dystrophy. *J Am Coll Cardiol* 1993;22:1927–1934.
- e126. Melacini P, Fanin M, Danieli GA, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. *Circulation* 1996;94:3168–3175.
- e127. Melo M, Lauriano V, Gentil V, et al. Becker and limb-girdle muscular dystrophies: a psychiatric and intellectual level comparative study. *Am J Med Genet* 1995;60:33–38.
- e128. Nicholson LV, Johnson MA, Bushby KM, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. *J Med Genet* 1993;30:745–751.

- e129. Nigro G, Comi LI, Politano L, et al. Evaluation of the cardiomyopathy in Becker muscular dystrophy. *Muscle Nerve* 1995;18:283–291.
- e130. Pradhan S. Valley sign in Becker muscular dystrophy and outliers of Duchenne and Becker muscular dystrophy. *Neurol India* 2004;52:203–205.
- e131. Ramelli GP, Joncourt F, Luetsch J, Weis J, Tolnay M, Burgunder JM. Becker muscular dystrophy with marked divergence between clinical and molecular genetic findings: case series. *Swiss Med Wkly* 2006;136:189–193.
- e132. Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. *Am Heart J* 1996;132:642–647.
- e133. Steare SE, Dubowitz V, Benatar A. Subclinical cardiomyopathy in Becker muscular dystrophy. *Br Heart J* 1992;68:304–308.
- e134. Stöllberger C, Finsterer J, Keller H, Mamoli B, Slany J. Progression of cardiac involvement in patients with myotonic dystrophy, Becker's muscular dystrophy and mitochondrial myopathy during a 2-year follow-up. *Cardiology* 1998;90:173–179.
- e135. Matsumura K, Nonaka I, Tomé FM, et al. Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin. *Am J Hum Genet* 1993;53:409–416.
- e136. Sveen ML, Jeppesen TD, Hauerslev S, Køber L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. *Brain* 2008;131:2824–2831.
- e137. Taşdemir HA, Cil E, Topaloğlu H, et al. Cardiorespiratory function in Duchenne and Becker muscular dystrophy. *Turk J Pediatr* 1996;38:307–314.
- e138. Muntoni F, Mateddu A, Cianchetti C, et al. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy. *J Neurol Neurosurg Psychiatry* 1993;56:26–31.
- e139. Nakamura A, Yoshida K, Fukushima K, et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. *J Clin Neurosci* 2008;15:757–763.
- e140. Nicholson LV, Johnson MA, Gardner-Medwin D, Bhattacharya S, Harris JB. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. *Acta Neuropathol* 1990;80:239–250.
- e141. Norman AM, Thomas NS, Kingston HM, Harper PS. Becker muscular dystrophy: correlation of deletion type with clinical severity. *J Med Genet* 1990;27:236–239.
- e142. Yilmaz A, Gdynia HJ, Baccouche H, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. *J Cardiovasc Magn Reson* 2008;10:50.
- e143. Yoshida K, Ikeda S, Nakamura A, et al. Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. *Muscle Nerve* 1993;16:1161–1166.
- e144. Young HK, Barton BA, Waisbren S, et al. Cognitive and psychological profile of males with Becker muscular dystrophy. *J Child Neurol* 2008;23:155–162.
- e145. Zaidman CM, Connolly AM, Malkus EC, Florence JM, Pestronk A. Quantitative ultrasound using backscatter analysis in Duchenne and Becker muscular dystrophy. *Neuromuscul Disord* 2010;20:805–809.

- e146. Zatz M, Rapaport D, Vainzof M, et al. Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. *J Neurol Sci* 1991;102:190–196.
- e147. Yazaki M, Yoshida K, Nakamura A, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. *Eur Neurol* 1999;42:145–149.
- e148. Sahashi K, Ibi T, Suoh H, et al. Immunostaining of dystrophin and utrophin in skeletal muscle of dystrophinopathies. *Intern Med* 1994;33:277–283.
- e149. Sánchez-Arjona MB, Rodríguez-Uranga JJ, Giles-Lima M, et al. Spanish family with myalgia and cramps syndrome. *J Neurol Neurosurg Psychiatry* 2005;76:286–289.
- e150. Veerapandiyan A, Shashi V, Jiang YH, Gallentine WB, Schoch K, Smith EC. Pseudometabolic presentation of dystrophinopathy due to a missense mutation. *Muscle Nerve* 2010;42:975–979.
- e151. Brabec P, Vondráček P, Klimes D, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. *Neuromuscul Disord* 2009;19:250–254.
- e152. Sultan A, Fayaz M. Prevalence of cardiomyopathy in Duchenne and Becker's muscular dystrophy. *J Ayub Med Coll Abbottabad* 2008;20:7–13.
- e153. Hanisch F, Grimm D, Zierz S, Deschauer M. Frequency of the FKRP mutation c.826C>A in isolated hyperCKemia and in limb girdle muscular dystrophy type 2 in German patients. *J Neurol* 2010;257:300–301.
- e154. Boito CA, Melacini P, Vianello A, et al. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. *Arch Neurol* 2005;62:1894–1899.
- e155. Brockington M, Yuva Y, Prandini P, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. *Hum Mol Genet* 2001;10:2851–2859.
- e156. Schwartz M, Hertz JM, Sveen ML, Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. *Neurology* 2005;64:1635–1637.
- e157. Kang PB, Feener CA, Estrella E, et al. LGMD2I in a North American population. *BMC Musculoskelet Disord* 2007;8:115.
- e158. dePaula F, Vieira N, Starling A, et al. Asymptomatic carriers for homozygous novel mutations in the FKRP gene: the other end of the spectrum. *Eur J Hum Genet* 2003;11:923–930.
- e159. Driss A, Amouri R, Ben Hamida C, et al. A new locus for autosomal recessive limb-girdle muscular dystrophy in a large consanguineous Tunisian family maps to chromosome 19q13.3. *Neuromuscul Disord* 2000;10:240–246.
- e160. Poppe M, Cree L, Bourke J, et al. The phenotype of limb-girdle muscular dystrophy type 2I. *Neurology* 2003;60:1246–1251.
- e161. Sveen ML, Jeppesen TD, Hauerslev S, Krag TO, Vissing J. Endurance training: an effective and safe treatment for patients with LGMD2I. *Neurology* 2007;68:59–61.
- e162. Frosk P, Greenberg CR, Tennese AA, et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. *Hum Mutat* 2005;25:38–44.
- e163. Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. *Ann Neurol* 2003;53:537–542.
- e164. Walter MC, Petersen JA, Stucka R, et al. FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. *J Med Genet* 2004;41:e50.

- e165. Rosales XQ, Moser SJ, Tran T, et al. Cardiovascular magnetic resonance of cardiomyopathy in limb girdle muscular dystrophy 2B and 2I. *J Cardiovasc Magn Reson* 2011;13:39.
- e166. Gaul C, Deschauer M, Tempelmann C, et al. Cardiac involvement in limb-girdle muscular dystrophy 2I: conventional cardiac diagnostic and cardiovascular magnetic resonance. *J Neurol* 2006;253:1317–1322.
- e167. Bourteel H, Vermersch P, Cuisset JM, et al. Clinical and mutational spectrum of limb-girdle muscular dystrophy type 2I in 11 French patients. *J Neurol Neurosurg Psychiatry* 2009;80:1405–1408.
- e168. Müller T, Krasnianski M, Witthaut R, Deschauer M, Zierz S. Dilated cardiomyopathy may be an early sign of the C826A Fukutin-related protein mutation. *Neuromuscul Disord* 2005;15:372–376.
- e169. Palmieri A, Manara R, Bello L, et al. Cognitive profile and MRI findings in limb-girdle muscular dystrophy 2I. *J Neurol* 2011;258:1312–1320.
- e170. Yilmaz A, Gdynia HJ, Ponfick M, Ludolph AC, Rösch S, Sehtem U. The proteoglycan-dystrophin complex in genetic cardiomyopathies--lessons from three siblings with limb-girdle muscular dystrophy-2I (LGMD-2I). *Clin Res Cardiol* 2011;100:611–615.
- e171. Wahbi K, Meune C, Hamouda el H, et al. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. *Neuromuscul Disord* 2008;18:650–655.
- e172. Kefi M, Amouri R, Chabrak S, Mechmeche R, Hentati F. Variable cardiac involvement in Tunisian siblings harboring FKRFP gene mutations. *Neuropediatrics* 2008;39:113–115.
- e173. Boriani G, Gallina M, Merlini L, et al. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. *Stroke* 2003;34:901–908.
- e174. Charniot J, Desnos M, Zerhouni K, et al. Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: a phenotypic study. *Eur J Heart Fail* 2006;8:249–256.
- e175. Mercuri E, Brown SC, Nihoyannopoulos P, et al. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. *Muscle Nerve* 2005;31:602–609.
- e176. Mercuri E, Poppe M, Quinlivan R, et al. Extreme variability of phenotype in patients with an identical missense mutation in the lamin A/C gene: from congenital onset with severe phenotype to milder classic Emery-Dreifuss variant. *Arch Neurol* 2004;61:690–694.
- e177. Sanna T, Dello Russo A, Toniolo D, et al. Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations. *Eur Heart J* 2003;24:2227–2236.
- e178. Smith GC, Kinali M, Prasad SK, et al. Primary myocardial dysfunction in autosomal dominant EDMD. A tissue Doppler and cardiovascular magnetic resonance study. *J Cardiovasc Magn Reson* 2006;8:723–730.
- e179. van der Kooi AJ, Ledderhof TM, de Voogt WG, et al. A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. *Ann Neurol* 1996;39:636–642.
- e180. Antoniadou L, Eftychiou C, Kyriakides T, Christodoulou K, Katritsis DG. Malignant mutation in the lamin A/C gene causing progressive conduction system disease and early sudden death in a family with mild form of limb-girdle muscular dystrophy. *J Interv Card Electrophysiol* 2007;19:1–7.

- e181. Bécane H-M, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. *Pacing Clin Electrophysiol* 2000;23:1661–1666.
- e182. Charniot JC, Pascal C, Bouchier C, et al. Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. *Hum Mutat* 2003;21:473–481.
- e183. Jakobs PM, Hanson EL, Crispell KA, et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. *J Card Fail* 2001;7:249–256.
- e184. Sundblom J, Stålberg E, Osterdahl M, et al. Bedside diagnosis of rippling muscle disease in CAV3 p.A46T mutation carriers. *Muscle Nerve* 2010;41:751–757.
- e185. Vorgerd M, Bolz H, Patzold T, Kubisch C, Malin JP, Mortier W. Phenotypic variability in rippling muscle disease. *Neurology* 1999;52:1453–1459.
- e186. Banwell BL, Russel J, Fukudome T, Shen XM, Stilling G, Engel AG. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. *J Neuropathol Exp Neurol* 1999;58:832–846.
- e187. Charlesworth A, Chiaverini C, Chevrant-Breton J, et al. Epidermolysis bullosa simplex with PLEC mutations: new phenotypes and new mutations [published online ahead of print Jan 5, 2013]. *Br J Dermatol* doi: 10.1111/bjd.12202.
- e188. Chavanas S, Pulkkinen L, Gache Y, et al. A homozygous nonsense mutation in the PLEC1 gene in patients with epidermolysis bullosa simplex with muscular dystrophy. *J Clin Invest* 1996;98:2196–2200.
- e189. Forrest K, Mellerio JE, Robb S, et al. Congenital muscular dystrophy, myasthenic symptoms and epidermolysis bullosa simplex (EBS) associated with mutations in the PLEC1 gene encoding plectin. *Neuromuscul Disord* 2010;20:709–711.
- e190. Gache Y, Chavanas S, Lacour JP, et al. Defective expression of plectin/HD1 in epidermolysis bullosa simplex with muscular dystrophy. *J Clin Invest* 1996;97:2289–2298.
- e191. Mellerio JE, Smith FJ, McMillian JR, et al. Recessive epidermolysis bullosa simplex associated with plectin mutations: infantile respiratory complications in two unrelated cases. *Br J Dermatol* 1997;137:898–906.
- e192. Natsuga K, Nishie W, Shinkuma S, et al. Plectin deficiency leads to both muscular dystrophy and pyloric atresia in epidermolysis bullosa simplex. *Hum Mutat* 2010;31:E1687–E1698.
- e193. Pulkkinen L, Smith FJ, Shimizu H, et al. Homozygous deletion mutations in the plectin gene (PLEC1) in patients with epidermolysis bullosa simplex associated with late-onset muscular dystrophy. *Hum Mol Genet* 1996;5:1539–1546.
- e194. Rouan F, Pulkkinen L, Meneguzzi G, et al. Epidermolysis bullosa: novel and de novo premature termination codon and deletion mutations in the plectin gene predict late-onset muscular dystrophy. *J Invest Dermatol* 2000;114:381–387.
- e195. Schara U, Tücke J, Mortier W, et al. Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation. *Eur J Pediatr* 2004;163:218–222.
- e196. Schröder R, Kunz WS, Rouan F, et al. Disorganization of the desmin cytoskeleton and mitochondrial dysfunction in plectin-related epidermolysis bullosa simplex with muscular dystrophy. *J Neuropathol Exp Neurol* 2002;61:520–530.
- e197. Smith FJ, Eady RA, Leigh IM, et al. Plectin deficiency results in muscular dystrophy with epidermolysis bullosa. *Nat Genet* 1996;13:450–457.

- e198. Takizawa Y, Shimizu H, Rouan F, et al. Four novel plectin gene mutations in Japanese patients with epidermolysis bullosa with muscular dystrophy disclosed by heteroduplex scanning and protein truncation tests. *J Invest Dermatol* 1999;112:109–112.
- e199. Yiu EM, Klausegger A, Waddell LB, et al. Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiency. *Muscle Nerve* 2011;44:135–141.
- e200. Selcen D, Juel VC, Hobson-Webb LD, et al. Myasthenic syndrome caused by plectinopathy. *Neurology* 2011;76:327–336.
- e201. Shimizu H, Takizawa Y, Pulkkinen L, et al. Epidermolysis bullosa simplex associated with muscular dystrophy: phenotype-genotype correlations and review of the literature. *J Am Acad Dermatol* 1999;41:950–956.
- e202. Takahashi Y, Rouan F, Uitto J, et al. Plectin deficient epidermolysis bullosa simplex with 27-year-history of muscular dystrophy. *J Dermatol Sci* 2005;37:87–93.
- e203. Patrizi A, Di Lernia V, Neri I, Badiali De Giorgi L, Masi M. Epidermolysis bullosa simplex associated with muscular dystrophy: a new case. *Pediatr Dermatol* 1994;11:342–345.
- e204. Niemi KM, Sommer H, Kero M, Kanerva L, Haltia M. Epidermolysis bullosa simplex associated with muscular dystrophy with recessive inheritance. *Arch Dermatol* 1988;124:551–554.
- e205. Natsuga K, Nishie W, Akiyama M, et al. Plectin expression patterns determine two distinct subtypes of epidermolysis bullosa simplex. *Hum Mutat* 2010;31:308–316.
- e206. Koss-Harnes, D, Jahnsen FL, Wiche G, Soyland E, Brandtzaeg P, Gedde-Dahl T Jr. Plectin abnormality in epidermolysis bullosa simplex Onga: non-responsiveness of basal keratinocytes to some anti-rat plectin antibodies. *Exp Dermatol* 1997;6:41–48.
- e207. Kunz M, Rouan F, Pulkkinen L, et al. Mutation reports: epidermolysis bullosa simplex associated with severe mucous membrane involvement and novel mutations in the plectin gene. *J Invest Dermatol* 2000;114:376–380.
- e208. Kurose K, Mori O, Hachisuka H, Shimizu H, Owaribe K, Hashimoto T. Cultured keratinocytes from plectin/HD1-deficient epidermolysis bullosa simplex showed altered ability of adhesion to the matrix. *J Dermatol Sci* 2000;24:184–189.
- e209. McLean WH, Pulkkinen L, Smith FJ, et al. Loss of plectin causes epidermolysis bullosa with muscular dystrophy: cDNA cloning and genomic organization. *Genes Dev* 1996;10:1724–1735.
- e210. Maselli RA, Arredondo J, Cagney O, et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. *Clin Genet* 2011;80:444–451.
- e211. McMillan JR, Akiyama M, Rouan F, et al. Plectin defects in epidermolysis bullosa simplex with muscular dystrophy. *Muscle Nerve* 2007;35:24–35.
- e212. Doriguzzi C, Palmucci L, Mongini T, et al. Congenital muscular dystrophy associated with familial junctional epidermolysis bullosa letalis. *Eur Neurol* 1993;33:454–460.
- e213. Fine JD, Stenn J, Johnson L, Wright T, Bock HG, Horiguchi Y. Autosomal recessive epidermolysis bullosa simplex. Generalized phenotypic features suggestive of junctional or dystrophic epidermolysis bullosa, and association with neuromuscular diseases. *Arch Dermatol* 1989;125:931–938.
- e214. Bolling MC, Pas HH, de Visser M, et al. PLEC1 mutations underlie adult-onset dilated cardiomyopathy in epidermolysis bullosa simplex with muscular dystrophy. *J Invest Dermatol* 2010;130:1178–1181.

- e215. Dang M, Pulkkinen L, Smith FJ, McLean WH, Uitto J. Novel compound heterozygous mutations in the plectin gene in epidermolysis bullosa with muscular dystrophy and the use of protein truncation test for detection of premature termination codon mutations. *Lab Invest* 1998;78:195–204.
- e216. Kim BJ, Ki CS, Kim JW, Sung DH, Choi YC, Kim SH. Mutation analysis of the GNE gene in Korean patients with distal myopathy with rimmed vacuoles. *J Hum Genet* 2006;51:137–140.
- e217. Li H, Chen Q, Liu F, et al. Clinical and molecular genetic analysis in Chinese patients with distal myopathy with rimmed vacuoles. *J Hum Genet* 2011;56:335–338.
- e218. Lu X, Pu C, Huang X, Liu J, Mao Y. Distal myopathy with rimmed vacuoles: clinical and muscle morphological characteristics and spectrum of GNE gene mutations in 53 Chinese patients. *Neurol Res* 2011;33:1025–1031.
- e219. Argov Z, Yarom R. “Rimmed vacuole myopathy” sparing the quadriceps. A unique disorder in Iranian Jews. *J Neurol Sci* 1984;64:33–43.
- e220. Nonaka I, Sunohara N, Ishiura S, Satoyoshi E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. *J Neurol Sci* 1981;51:141–155.
- e221. Nonaka I, Sunohara N, Satoyoshi E, Terasawa K, Yonemoto K. Autosomal recessive distal muscular dystrophy: a comparative study with distal myopathy with rimmed vacuole formation. *Ann Neurol* 1985;17:51–59.
- e222. Knoblauch H, Geier C, Adams S, et al. Contractures and hypertrophic cardiomyopathy in a novel FHL1 mutation. *Ann Neurol* 2010;67:136–140.
- e223. Schessl J, Columbus A, Hu Y, et al. Familial reducing body myopathy with cytoplasmic bodies and rigid spine revisited: identification of a second LIM domain mutation in FHL1. *Neuropediatrics* 2010;41:43–46.
- e224. Selcen D, Bromberg MB, Chin SS, Engel AG. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. *Neurology* 2011;77:1951–1959
- e225. Shalaby S, Hayashi YK, Goto K, et al. Rigid spine syndrome caused by a novel mutation in four-and-a-half LIM domain 1 gene (FHL1). *Neuromuscul Disord* 2008;18:959–961.
- e226. Nakano S, Engel AG, Waclawik AJ, Emslie-Smith AM, Busis NA. Myofibrillar myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. *J Neuropathol Exp Neurol* 1996;55:549–562.
- e227. De Bleecker JL, Engel AG, Ertl BB. Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins. *J Neuropathol Exp Neurol* 1996;55:563–577.
- e228. Griggs R, Vihola A, Hackman P, et al. Zaspopathy in a large classic late-onset distal myopathy family. *Brain* 2007;130:1477–1484.
- e229. Sarparanta J, Jonson PH, Golzio C, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. *Nat Genet* 2012;44:450–455, S1–S2.
- e230. Wallgren-Pettersson C, Lehtokari VL, Kalimo H, et al. Distal myopathy caused by homozygous missense mutations in the nebulin gene. *Brain* 2007;130:1465–1476.
- e231. Lehtokari VL, Pelin K, Herczegfalvi A, et al. Nemaline myopathy caused by mutations in the nebulin gene may present as a distal myopathy. *Neuromuscul Disord* 2011;21:556–562.

- e232. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. *Ann Neurol* 2010;68:629–638.
- e233. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. *Ann Neurol* 2009;66:290–297.
- e234. Herson S, Hentati F, Rigolet A, et al. A phase I trial of adeno-associated virus serotype 1- γ -sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. *Brain* 2012;135:483–492.
- e235. Neumeyer AM, Cros D, McKenna-Yasek D, et al. Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. *Neurology* 1998;51:589–592.
- e236. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. *Ann Neurol* 2008;63:561–571.
- e237. Bäckman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. *Neuromuscul Disord* 1995;5:233–241.
- e238. Cittadini A, Ines Comi L, Longobardi S, et al. A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies. *Eur Heart J* 2003;24:664–672.
- e239. Sandin-aldehag A, Jonsson H. Evaluation of a hand training programme for patients with Welander distal myopathy. *Scand J Occup Ther* 2003;10:188–192.
- e240. Sunnerhagen KS, Darin N, Tajsharghi H, Oldfors A. The effects of endurance training in persons with a hereditary myosin myopathy. *Acta Neurol Scand* 2004;110:80–86.
- e241. Tajsharghi H, Sunnerhagen KS, Darin N, Kyllerman M, Oldfors A. Induced shift in myosin heavy chain expression in myosin myopathy by endurance training. *J Neurol* 2004;251:179–183.
- e242. Politano L, Nigro V, Passamano L, et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. *Neuromuscul Disord* 2001;11:178–185.
- e243. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2009;73:1218–1226.
- e244. Prater SN, Banugaria SG, DeArme SM, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. *Genet Med* 2012;14:800–810.
- e245. Barba-Romero MA, Barrot E, Bautista-Lorite J, et al. Clinical guidelines for late-onset Pompe disease. *Rev Neurol* 2012;54:497–507.
- e246. Groh WJ. Arrhythmias in the muscular dystrophies. *Heart Rhythm* 2012;9:1890–1895.
- e247. Kwon HW, Kwon BS, Kim GB, et al. The effect of enalapril and carvedilol on left ventricular dysfunction in middle childhood and adolescent patients with muscular dystrophy. *Korean Circ J* 2012;42:184–191.
- e248. Bushby K, Finkel R, Birnkrant DJ, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol* 2010;9:177–189.
- e249. Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and

cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2009;73:1227–1233.

- e250. Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM. Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. *Arch Phys Med Rehabil* 1993;74:711–715.
- e251. Kilmer DD, McCrory MA, Wright NC, Aitkens SG, Bernauer EM. The effect of a high resistance exercise program in slowly progressive neuromuscular disease. *Arch Phys Med Rehabil* 1994;75:560–563.
- e252. Wright NC, Kilmer DD, McCrory MA, Aitkens, SG, Holcomb BJ, Bernauer EM. Aerobic walking in slowly progressive neuromuscular disease: effect of a 12-week program. *Arch Phys Med Rehabil* 1996;77:64–69.